At a glance
ClinicalIndex Comparison RecordN/ACompleted· 164 enrolled
Drug / intervention
Point of Care Autonomous AI diabetic retinopathy examother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Autonomous AI for Diabetic Retinopathy Screening in Youth (AI-DR): A Randomized Control Trial
In Brief
A clinical study evaluating Point of Care Autonomous AI diabetic retinopathy exam for Type 1 Diabetes and Type 2 Diabetes. Completed, enrolled 164 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if providing in clinic point-of-care autonomous AI diabetic retinopathy exams improves screening rates compared to standard of care referral to an eye care provider, in a randomized control trial in a racially and ethnically diverse cohort of youth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes, Type 2 Diabetes
CountriesUnited States
CollaboratorsNational Eye Institute (NEI)
Timeline
N/ACompletedFinished
20222023202420252026
First PostedNov 2021
Enrollment StartNov 2021
Primary CompletionDec 2022
Study CompletionDec 2022
TodayJul 2026
First PostedNov 23, 2021
Enrollment StartNov 24, 2021
Primary CompletionDec 6, 2022
Study CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 4.6 years ago
Interventions
Point of Care Autonomous AI diabetic retinopathy examother
Participants will get a point of care diabetic retinopathy eye exam using autonomous AI. Those that test positive will be referred to Eye Care Provider for dilated eye exam.